Graphite Bio is set to merge with LENZ Therapeutics through a reverse merger, via an all-stock transaction. The merged company will continue to operate under the name LENZ Therapeutics and trade on the Nasdaq under the ticker symbol “LENZ”. The merged entity will focus on advancing LENZ’s pipeline candidates intended to address presbyopia, with an estimated US market opportunity exceeding $3bn. The transaction is expected to close in Q1 2024.
Found in the wild: The world’s first unkillable UEFI bootkit for Linux
Security firm ESET has found the first known example of a Linux UEFI bootkit, a type of malware that infects the Unified Extensible Firmware Interface.
